Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price
on Sep 15, 2025
Y-mAbs Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 85.39 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 | Upgrade
|
| Revenue Growth (YoY) | -1.34% | 3.38% | 29.96% | 87.03% | 68.18% | - | Upgrade
|
| Cost of Revenue | 15.8 | 15.25 | 11.42 | 7.57 | 2.51 | 2.2 | Upgrade
|
| Gross Profit | 69.58 | 72.43 | 73.4 | 57.7 | 32.38 | 18.55 | Upgrade
|
| Selling, General & Admin | 44.76 | 50.13 | 44.5 | 52.47 | 56.94 | 45.9 | Upgrade
|
| Research & Development | 42.94 | 47.41 | 50.09 | 88.55 | 90.88 | 92.58 | Upgrade
|
| Operating Expenses | 87.7 | 97.54 | 94.59 | 141.02 | 147.82 | 138.48 | Upgrade
|
| Operating Income | -18.11 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 | Upgrade
|
| Interest Expense | - | - | - | - | -1.85 | - | Upgrade
|
| Interest & Investment Income | 6.07 | 3.43 | 4.28 | 0.64 | - | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.04 | -2.04 | 0.52 | - | - | 0.58 | Upgrade
|
| EBT Excluding Unusual Items | -14.08 | -23.72 | -16.38 | -82.68 | -117.29 | -119.34 | Upgrade
|
| Merger & Restructuring Charges | -3.97 | -1.52 | -4.48 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 62.01 | - | Upgrade
|
| Asset Writedown | - | - | - | -0.62 | - | - | Upgrade
|
| Legal Settlements | -3.85 | -3.85 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.72 | -0.72 | - | -12.28 | - | - | Upgrade
|
| Pretax Income | -22.62 | -29.81 | -20.87 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Income Tax Expense | -0.39 | -0.15 | 0.56 | - | - | - | Upgrade
|
| Net Income | -22.22 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Net Income to Common | -22.22 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 44 | 44 | 44 | 43 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 44 | 44 | 44 | 43 | 40 | Upgrade
|
| Shares Change (YoY) | 2.79% | 1.57% | -0.13% | 1.21% | 7.64% | 14.03% | Upgrade
|
| EPS (Basic) | -0.49 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 | Upgrade
|
| EPS (Diluted) | -0.49 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 | Upgrade
|
| Free Cash Flow | -17.92 | -15.71 | -27.23 | -75.92 | -103.22 | -91.41 | Upgrade
|
| Free Cash Flow Per Share | -0.40 | -0.35 | -0.62 | -1.74 | -2.39 | -2.28 | Upgrade
|
| Gross Margin | 81.49% | 82.61% | 86.54% | 88.41% | 92.80% | 89.38% | Upgrade
|
| Operating Margin | -21.21% | -28.64% | -24.98% | -127.66% | -330.78% | -578.00% | Upgrade
|
| Profit Margin | -26.03% | -33.83% | -25.26% | -146.43% | -158.40% | -575.12% | Upgrade
|
| Free Cash Flow Margin | -20.99% | -17.92% | -32.11% | -116.32% | -295.79% | -440.51% | Upgrade
|
| EBITDA | -17.77 | -24.58 | -20.46 | -82.48 | -114.65 | -119.54 | Upgrade
|
| EBITDA Margin | -20.81% | -28.03% | -24.12% | -126.37% | - | - | Upgrade
|
| D&A For EBITDA | 0.35 | 0.54 | 0.74 | 0.84 | 0.78 | 0.4 | Upgrade
|
| EBIT | -18.11 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 | Upgrade
|
| EBIT Margin | -21.21% | -28.64% | -24.98% | -127.66% | - | - | Upgrade
|
| Revenue as Reported | 85.39 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.